FIELD: medicine, pharmaceutics.
SUBSTANCE: there are presented a composition and a method for producing it. The characterised composition contains: an effective amount of a viral antigen, which represents a live attenuated rotavirus pre-processed in 0.1% human serum albumin, and a pharmaceutically acceptable buffer. A method for producing a composition involves growing Vero cell culture pre-cultured in the presence of 5% foetal calf serum and 0.1% human serum albumin, infecting the above Vero cell culture with the live attenuated rotavirus, propagating the virus in the cell culture and adding a pharmaceutically acceptable buffer to the above virus.
EFFECT: presented inventions can be used to prevent rotavirus infection and/or rotavirus gastroenteritis.
11 cl, 17 dwg, 4 tbl, 2 ex
| Title | Year | Author | Number |
|---|---|---|---|
| NEW ROTAVIRAL VACCINE COMPOSITIONS AND METHOD OF OBTAINING THE ABOVE COMPOSITIONS | 2013 |
|
RU2643929C2 |
| ATTENUATED INFLUENZA VECTORS FOR THE PREVENTION AND/OR TREATMENT OF INFECTIOUS DISEASES, AS WELL AS FOR CANCER TREATMENT | 2015 |
|
RU2628690C2 |
| SWINE VIRUS VACCINES STABLE IN LIQUID FORM | 2015 |
|
RU2695523C2 |
| STABILISING EXCIPIENT FOR VACCINE WITH INACTIVATED WHOLE VIRUSES | 2010 |
|
RU2560675C2 |
| DRY VACCINE COMPOSITIONS STABLE AT ROOM TEMPERATURE | 2014 |
|
RU2826263C2 |
| VACCINES, STABLE AT ROOM TEMPERATURE | 2014 |
|
RU2740920C2 |
| STABILISING COMPOSITION FOR DRY STORAGE OF BIOLOGIC MATERIALS (VERSIONS) | 2011 |
|
RU2573324C2 |
| ATTENUATED GRIPPOSE VECTOR AND MUCOSAL UNIVERSAL GRIPPOSE VACCINE ON ITS BASIS | 2016 |
|
RU2660562C2 |
| STABLE DRY POWDER COMPOSITION CONTAINING BIOLOGICALLY ACTIVE MICROORGANISMS AND/OR BIOLOGICALLY ACTIVE MATERIALS AND METHOD OF ITS PRODUCTION | 2010 |
|
RU2567668C2 |
| LIQUID STABLE VIRAL VACCINES | 2013 |
|
RU2641970C2 |
